The United Kingdom has approved using anastrozole to prevent breast cancer in postmenopausal women who are at moderate to high risk, with the goal of reducing the overall incidence by about half. This development was reported by Speech. Citation: Speech
An estimated 2.3 million people are diagnosed with breast cancer worldwide each year, with women forming the majority of cases. If even a portion of these cancers can be prevented, countless lives could be saved. The UK became the first country to authorize anastrozole for cancer prevention in women after menopause who carry a moderate to high risk. Earlier, anastrozole had already received approval for treating breast cancer within the UK. Citation: Speech
The drug works by lowering estrogen levels. In roughly eight out of ten breast cancer cases, estrogen supports tumor growth, especially in the early stages. Anastrozole blocks the aromatase enzyme, which is responsible for producing estrogen after menopause. Prior studies have indicated the medication helps prevent the recurrence of estrogen-sensitive breast cancers in patients who have undergone chemotherapy or surgery. Citation: Speech
However, dropping estrogen can worsen menopausal symptoms and raise fracture risk. For this reason, medical guidance typically recommends using anastrozole for no more than five years and to weigh the benefits against potential harms on an individual basis. Citation: Speech
There is also concern about imaging procedures, as some scans expose patients to radiation. This underscores the importance of thoughtful screening strategies and the careful selection of who should receive preventive drugs like anastrozole. Citation: Speech